OKYO Pharma Limited (NASDAQ:OKYO – Get Free Report) saw a large decline in short interest in the month of March. As of March 15th, there was short interest totalling 217,900 shares, a decline of 35.5% from the February 28th total of 338,000 shares. Currently, 0.9% of the company’s shares are sold short. Based on an average daily trading volume, of 178,700 shares, the short-interest ratio is currently 1.2 days.
OKYO Pharma Stock Performance
OKYO stock traded down $0.08 during trading hours on Friday, reaching $1.35. The stock had a trading volume of 44,082 shares, compared to its average volume of 114,402. The stock has a 50-day simple moving average of $1.21 and a 200 day simple moving average of $1.12. OKYO Pharma has a fifty-two week low of $0.81 and a fifty-two week high of $1.74.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright restated a “buy” rating and set a $7.00 target price on shares of OKYO Pharma in a report on Tuesday, February 18th.
OKYO Pharma Company Profile
OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease.
Featured Stories
- Five stocks we like better than OKYO Pharma
- How to Capture the Benefits of Dividend Increases
- Venezuelan Tariffs Could Power These 3 Diesel-Driven Winners
- Transportation Stocks Investing
- MarketBeat Week in Review – 03/24 – 03/28
- Insider Trading – What You Need to Know
- Should You Buy UPS Stock Now? Deep Dive Into Its 5-Year Low
Receive News & Ratings for OKYO Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OKYO Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
